$MRK (Merck & Co. Inc.)

$MRK {{ '2015-07-28T14:17:19+0000' | timeago}} • Webcast

$MRK 2Q15 Q&A: Bristow of BofAML asked about the opportunity in Hep C market and Adam told Hep C market represents a very significant opportunity for Merck. At past, around 100,000 to 120,000 at maximum were treated, but now it’s 170,000 to 200,000. Hep C market remains very attractive and Merck is excited about getting into that market place.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$MRK {{ '2017-07-20T14:29:27+0000' | timeago}} • Announcement

$MRK announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for its 100 units/mL insulin glargine injection, a follow-on biologic basal insulin in a pre-filled dosing device.

$MRK {{ '2017-07-06T12:50:08+0000' | timeago}} • Announcement

Pharma company $MRK will present its HIV portfolio and pipeline at the 9th IAS Conference on HIV Science. The presentations include late-breaker abstracts from two phase-3 pivotal clinical trials and a phase-1 study of MK-8591, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor in adult patients with HIV-1 infection.

$MRK {{ '2017-07-05T22:11:39+0000' | timeago}} • Announcement

$MRK said the US FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combination studies of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. The FDA has determined that the risks of KEYTRUDA outweigh any potential benefit for patients with multiple myeloma.

$MRK {{ '2017-06-27T14:06:02+0000' | timeago}} • Announcement

$MRK provided update on Reveal outcomes study of anacetrapid. $MRK plans to review the results of the trial with external experts, and will consider whether to file new drug applications with the FDA and other regulatory agencies. The results will be presented at the European Society of Cardiology meeting on Aug. 29, 2017.

$MRK {{ '2017-06-27T14:04:38+0000' | timeago}} • Announcement

$MRK announced that the Reveal (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events compared to placebo in patients at risk for cardiac events who are already receiving an effective LDL-C lowering regimen.

$MRK {{ '2017-06-12T11:25:01+0000' | timeago}} • Announcement

$MRK, in partnership with $PFE, announced that two Phase 3 studies of ertugliflozin, an investigational oral drug to help improve glucose level control in adults with type 2 diabetes, met their primary endpoints.

$MRK {{ '2017-05-23T17:54:08+0000' | timeago}} • Announcement

$MRK's BoD declared a quarterly dividend of $0.47 per share of its common stock for 3Q17. The dividend will be payable on July 10, 2017 to shareholders of record at the close of business on June 15, 2017.

$MRK {{ '2017-05-02T13:03:59+0000' | timeago}} • Webcast

$MRK said that for HCV, it is seeing good progress with ZEPATIER, which is not only seen in the US but also in Europe & Japan. Looking at the HCV market, the market is large and has good opportunities, but would be played out over many years. However, $MRK is seeing a reduction in patients being treated in 2017 vs. 2016, which is going to continue.

$MRK {{ '2017-05-02T12:52:09+0000' | timeago}} • Webcast

$MRK stated that on the GM outlook for the rest of the year, the company continues to expect a moderate increase over 2016. In 1Q17, $MRK had a strong GM, driven largely by CapEx and discards.

$MRK {{ '2017-05-02T12:12:07+0000' | timeago}} • Infographic

$MRK Merck & Co. Inc. Earnings AlphaGraphics: Q1 2017 highlights

$MRK {{ '2017-05-02T11:17:22+0000' | timeago}} • Announcement

In 1Q17, $MRK's pharmaceutical sales rose 1% to $8.2Bil, driven by oncology, hepatitis C and vaccines. Growth in oncology was due to higher sales of KEYTRUDA. Animal Health sales totaled $939MM, an increase of 13% YoY. The growth was primarily due to sales increases in companion animal products, driven by BRAVECTO line of products.

$MRK {{ '2017-05-02T11:12:00+0000' | timeago}} • Announcement

$MRK narrowed and raised its FY17 GAAP EPS range to be between $2.51 and $2.63. FY17 non-GAAP EPS range was narrowed and raised to the range of $3.76-3.88. Meanwhile, it narrowed and raised its revenue range for the period to be between $39.1Bil and $40.3Bil.

$MRK {{ '2017-05-02T11:08:00+0000' | timeago}} • Announcement

Pharmaceutical giant $MRK posted worldwide sales of $9.4Bil in 1Q17, up 1%, driven by the continued momentum of KEYTRUDA in the treatment of tumors, as well as strength of other franchises and animal health. Net income was $1.55Bil, or $0.56 per share, up from $1.13Bil, or $0.40 per share in 1Q16. Adjusted for special items, EPS stood at $0.88.

$MRK {{ '2017-04-24T15:14:04+0000' | timeago}} • Announcement

$MRK announced new phase 2 data on investigational triple combination therapy MK-3682B for chronic hepatitis C virus (HCV) genotype (GT) 1 infection for whom treatment with approved direct-acting antiviral regimens had failed.

$MRK {{ '2017-04-11T12:38:37+0000' | timeago}} • Announcement

$MRK announced that Dr John Noseworthy, CEO of Mayo Clinic, has been nominated to stand for election to it BoD. The election of Dr Noseworthy will take place at Merck’s Annual Meeting of Shareholders on May 23, 2017. With the proposed addition of Dr Noseworthy and the planned retirement of Robert Kidder, the Merck board will have 13 members.

$INCY {{ '2017-03-31T13:23:43+0000' | timeago}} • Announcement

$INCY and $MRK provide additional details on collaboration investigating Epacadostat and Keytruda. Keytruda is $MRK's anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).

$INCY {{ '2017-03-31T13:22:20+0000' | timeago}} • Announcement

$INCY and $MRK announced additional details of their clinical development program investigating the combination of epacadostat, $INCY's investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), $MRK's anti-PD-1 tumor therapy.

$MRK {{ '2017-03-24T14:24:36+0000' | timeago}} • Announcement

$MRK said the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of Keytruda (pembrolizumab) for the treatment of Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed BV.

$MRK {{ '2017-03-06T14:30:21+0000' | timeago}} • Announcement

$MRK and $PFE announced that the European Medicines Agency has validated for review three Marketing Authorization Applications for ertugliflozin monotherapy and the two fixed-dose combination products.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
PRGO (Perrigo Company Public Limited Company)
Wednesday, May 31 2017 - 12:30pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, May 11 2017 - 12:30pm
PMC (PharMerica Corporation)
Wednesday, May 10 2017 - 2:00pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, May 9 2017 - 3:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
RARE (Ultragenyx Pharmaceutical Inc.)
Thursday, May 4 2017 - 9:00pm
CBM (Cambrex Corporation.)
Thursday, May 4 2017 - 12:30pm
Q (Quintiles Transnational Holdings Inc.)
Wednesday, May 3 2017 - 1:00pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
WCG (WellCare Health Plans, Inc.)
Wednesday, May 3 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
VAR (Varian Medical Systems, Inc.)
Wednesday, April 26 2017 - 9:00pm

AlphaGraphics you may like